immunogen
efficaci
betapropiolactoneinactiv
caprin
herpesviru
vaccin
adjuv
tm
test
goat
follow
two
subcutan
immun
goat
develop
high
titer
serum
vagin
igg
high
serum
viru
neutral
vn
titer
peripher
blood
mononuclear
cell
pbmc
stimul
vitro
inactiv
produc
high
level
solubl
ifngamma
exhibit
high
frequenc
ifngamma
produc
cell
solubl
undetect
hand
control
goat
receiv
inactiv
vaccin
without
adjuv
produc
low
serum
antibodi
respons
vagin
challeng
virul
perform
vaccin
goat
goat
assess
efficaci
two
vaccin
vagin
diseas
detect
goat
vaccin
inactiv
plu
tm
anim
undetect
level
infecti
challeng
viru
vagin
wash
goat
vaccin
inactiv
absenc
adjuv
exhibit
less
sever
diseas
compar
goat
shed
titer
challeng
viru
similar
goat
detect
quantit
latent
dna
sacral
ganglia
challeng
goat
reveal
inactiv
plu
tm
vaccin
abl
significantli
reduc
latent
viral
load
compar
either
goat
goat
vaccin
inactiv
absenc
adjuv
thu
vaccin
compos
inactiv
plu
tm
adjuv
strongli
immunogen
induc
effect
immun
vagin
infect
goat
caprin
herpesviru
alphaherpesviru
respons
lethal
system
infect
kid
mild
subclin
infect
adult
goat
clinic
manifest
adult
goat
involv
respiratori
reproduct
tract
depend
site
viru
entri
although
infect
preferenti
genit
mucosa
follow
primari
genit
infect
viru
replic
mucos
epithelium
spread
sacral
ganglia
establish
latenc
genit
infect
character
pain
erythematousoedemat
lesion
evolv
vesicl
ulcer
heal
two
week
balanoposth
vagin
infertil
abort
often
observ
primari
recurr
infect
although
infect
distribut
worldwid
major
econom
loss
occur
mediterranean
countri
vaccin
commerci
avail
ideal
vaccin
prevent
primari
infect
replic
vagin
mucosa
interfer
establish
latenc
fact
reactiv
latent
viru
mucos
shed
respons
transmiss
anim
flock
newborn
interestingli
share
sever
biolog
featur
human
tropism
vagin
epithelium
type
genit
lesion
establish
latenc
sacral
ganglia
experiment
studi
goat
shown
parenter
immun
inactiv
plu
montanid
isa
tm
vagin
immun
inactiv
plu
provid
partial
protect
vagin
challeng
virul
addit
intranas
vaccin
live
attenu
ge
neg
bovin
herpesviru
vaccin
shown
confer
partial
crossreact
protect
goat
challeng
vagin
collect
studi
suggest
either
viru
neutral
vn
activ
serum
vagin
iga
contribut
protect
although
precis
role
play
antibodi
respons
protect
vagin
infect
need
specif
address
addit
role
play
cellmedi
immun
respons
control
infect
reactiv
remain
unknown
present
studi
undertaken
determin
use
potent
adjuv
could
augment
immunogen
protect
efficaci
inactiv
vaccin
end
goat
subcutan
immun
betapropiolactoneinactiv
vaccin
tm
adjuv
oilinwat
emuls
tm
employ
sinc
licens
human
use
influenza
vaccin
sinc
larg
safeti
databas
known
induc
antibodi
cellmedi
immun
respons
variou
preclin
model
human
although
never
test
efficaci
rumin
result
present
herein
provid
first
evid
addit
tm
adjuv
greatli
enhanc
immunogen
protect
afford
inactiv
vaccin
experi
approv
italian
ministri
health
prot
n
carri
univers
bari
accord
nation
guid
care
use
experiment
anim
twentyeight
femal
goat
year
mix
breed
employ
studi
vaccin
goat
test
insur
neg
serum
vn
antibodi
serum
igg
vagin
igg
strain
use
throughout
studi
prepar
inactiv
vaccin
ii
antigen
elisa
iii
inoculum
vagin
challeng
briefli
viru
stock
obtain
infect
madin
darbi
bovin
kidney
cell
mdbk
atcc
lgc
standard
milan
itali
grown
dmem
lonza
walkersville
usa
viral
titer
tissu
cultur
infecti
dose
tcid
ml
viral
suspens
test
found
free
bacteri
fungal
contamin
vaccin
prepar
viru
inactiv
betapropiolacton
describ
tempesta
et
al
total
amount
protein
inactiv
suspens
mgml
vagin
challeng
perform
pipet
four
millilit
virul
suspens
tcid
ml
vagin
lumen
anim
vaccin
anim
adjuv
employ
studi
oilinwat
emuls
tm
novarti
vaccin
diagnost
siena
itali
twentyeight
goat
receiv
either
ml
inactiv
tcid
ml
plu
ml
steril
salin
solut
receiv
ml
inactiv
emulsifi
ml
tm
left
unvaccin
anim
serv
control
challeng
studi
goat
employ
perform
four
independ
experi
conduct
follow
experi
n
goat
one
goat
receiv
inactiv
two
goat
receiv
inactiv
plu
tm
one
goat
remain
unvaccin
experi
n
goat
one
goat
receiv
inactiv
four
goat
receiv
inactiv
plu
tm
one
goat
remain
unvaccin
experi
n
goat
three
goat
receiv
inactiv
three
goat
receiv
inactiv
plu
tm
three
goat
remain
unvaccin
experi
n
goat
three
goat
receiv
inactiv
three
goat
receiv
inactiv
plu
tm
three
goat
remain
unvaccin
prepar
vaccin
immedi
inject
subcutan
neck
goat
vaccin
two
dose
vaccin
one
dose
day
one
dose
day
close
inspect
inject
site
evid
local
reaction
granuloma
abscess
goat
vaccin
inactiv
without
adjuv
tm
system
advers
reaction
observ
goat
includ
studi
blood
sampl
asept
obtain
jugular
vein
immun
day
day
second
immun
day
heparin
tube
employ
collect
whole
blood
cellular
analys
serum
obtain
centrifug
nonheparin
glass
tube
rpm
min
beckman
microfug
fullerton
usa
vagin
sampl
collect
flush
vagin
lumen
steril
pipett
contain
ml
steril
pb
sampl
centrifug
rpm
min
supernat
collect
sera
vagin
wash
store
test
viru
neutral
vn
assay
perform
describ
elsewher
briefli
sera
heatinactiv
min
serial
dilut
start
individu
sampl
mix
tcid
strain
microtit
plate
corn
inc
ny
usa
plate
kept
room
temperatur
min
mdbk
cell
ad
well
incub
day
co
endpoint
titer
determin
use
spearmankarb
method
express
highest
serum
dilut
abl
neutral
cytopath
effect
elisa
test
employ
determin
titer
igg
iga
serum
vagin
wash
titer
serum
subclass
describ
elsewher
briefli
polystyren
plate
nunc
roskild
denmark
coat
dilut
carbon
buffer
incub
overnight
shaker
block
wash
step
serial
dilut
individu
sera
vagin
wash
ad
duplic
well
incub
overnight
plate
wash
hrpconjug
rabbit
antigoat
igg
bethyl
montgomeri
usa
hrpconjug
rabbit
antigoat
iga
bethyl
hrpconjug
sheep
antibovin
bethyl
hrpconjug
sheep
antibovin
bethyl
ad
well
incub
overnight
final
wash
addit
abt
colorimetr
reaction
measur
nm
elisa
plate
reader
biorad
hercul
usa
vitro
ifngamma
measur
peripher
blood
mononuclear
cell
pbmc
isol
heparin
blood
sampl
use
standard
densitygradi
separ
procedur
lympholyt
cedarlan
laboratori
ltd
burlington
nc
usa
wash
twice
steril
hbss
pbmc
viabl
cellsml
incub
day
co
complet
medium
rpmi
supplement
uml
penicillin
mgml
streptomycin
mm
lglutamin
heatinactiv
fb
determin
cytokin
secret
pbmc
cultur
stimul
inactiv
mgml
sinc
previou
studi
show
optim
cytokin
secret
induc
amount
antigen
mdbk
cell
lysat
without
viru
stimul
cytokin
secret
thu
exclud
cellspecif
cytokin
respons
cultur
left
unstimul
serv
neg
control
experi
parallel
cultur
set
pbmc
isol
goat
vaccin
inactiv
ii
vaccin
inactiv
plu
tm
iii
level
solubl
cultur
supernat
measur
use
commerci
avail
elisa
kit
thermo
scientif
shown
abl
detect
caprin
test
perform
accord
manufactur
instruct
level
solubl
ifngamma
cultur
supernat
determin
use
commerci
avail
elisa
kit
bovigam
prionic
victoria
australia
modif
sinc
quantif
achiev
use
bovin
recombin
ifngamma
thermo
scientif
standard
sensit
ifngamma
kit
pgml
measur
ifngamma
spotform
cell
ifngamma
sfc
commerci
avail
elispot
kit
specif
bovin
ifngamma
crossreact
caprin
ifngamma
employ
test
perform
accord
manufactur
instruct
particular
pbmc
suspens
directli
cultur
onto
nitrocellulosewel
plate
includ
kit
thermo
scientif
rockford
il
usa
ifngamma
sfc
count
aid
dissect
microscop
leica
leica
microsystem
srl
milan
itali
anim
vaccin
unvaccin
subject
vagin
challeng
ml
virul
tcid
ml
kept
observ
day
challeng
perform
two
week
follow
second
immun
ie
day
post
first
immun
vaccin
anim
follow
challeng
viral
shed
measur
accord
tempesta
et
al
briefli
vagin
swab
collect
daili
place
ml
dmem
centrifug
rpm
min
supernat
collect
ml
treat
ml
antibiot
solut
iuml
penicillin
mgml
streptomycin
mgml
amphotericin
b
incub
min
room
temperatur
sampl
serial
dilut
inocul
quadrupl
onto
mdbk
cell
place
microtit
plate
corn
plate
incub
day
co
viru
titer
measur
previous
describ
challeng
goat
also
examin
daili
evalu
sever
infect
bodi
temperatur
measur
gener
local
clinic
sign
record
ie
hyperemia
edema
lesion
pain
cumul
clinic
score
determin
anim
grade
clinic
sign
follow
absent
mild
moder
sever
temperatur
increment
normal
normal
bodi
temperatur
rang
grade
follow
realtim
pcr
assay
employ
detect
quantit
genom
dna
vagin
swab
collect
daili
day
challeng
sacral
ganglia
excis
one
month
challeng
assay
conduct
previous
report
briefli
sampl
ie
ml
swab
mg
ganglion
process
extract
dna
qiagen
spa
itali
primer
probe
dna
standard
employ
realtim
pcr
assay
design
target
conserv
region
gc
gene
strain
intern
control
canin
parvoviru
type
dna
includ
assay
exclud
loss
dna
extract
amplif
step
analyt
perform
realtim
pcr
assay
employ
studi
compar
report
previous
detect
limit
assay
standard
dna
ml
templat
data
express
arithmet
mean
sd
log
transform
vn
titer
ii
transform
serum
iggvagin
iggserum
igg
subclass
titer
iii
solubl
ifngamma
level
iv
number
ifngamma
sfc
v
log
transform
viral
shed
titer
vi
number
genom
vagin
swab
vi
clinic
score
data
latenc
sacral
ganglia
express
arithmet
mean
sem
log
transform
number
genom
data
record
day
day
post
challeng
ie
vagin
shed
titer
number
genom
vagin
swab
clinic
score
use
calcul
area
curv
auc
data
analyz
oneway
anova
test
follow
tukey
posthoc
test
multipl
comparison
differ
log
serum
titer
within
vaccin
group
analyz
student
ttest
softwar
r
version
employ
perform
test
p
valu
less
consid
signific
studi
immunogen
inactiv
plu
tm
vaccin
vn
antibodi
igg
specif
measur
serum
paramet
measur
sera
drawn
vaccin
day
ten
day
first
dose
vaccin
day
ten
day
second
dose
vaccin
day
order
evalu
adjuv
activ
tm
goat
vaccin
inactiv
use
control
goat
serv
background
control
note
day
sampl
vaccin
goat
undetect
level
vn
serum
antibodi
ii
serum
igg
iii
vagin
igg
inclus
criteria
current
studi
shown
figur
first
dose
vaccin
ie
day
sera
goat
exhibit
variabl
vn
antibodi
respons
particular
goat
vaccin
inactiv
averag
vn
titer
slightli
goat
log
goat
log
goat
vaccin
inactiv
goat
vaccin
inactiv
plu
tm
show
averag
vn
titer
log
higher
goat
higher
goat
vaccin
inactiv
administr
second
dose
vaccin
ie
day
post
immun
fig
vn
titer
increas
goat
immun
reach
averag
titer
log
higher
anim
contrast
goat
vaccin
inactiv
plu
tm
develop
significantli
elev
vn
titer
log
day
approxim
higher
goat
higher
goat
vaccin
inactiv
figur
show
first
dose
vaccin
ie
day
post
immun
titer
serum
igg
goat
vaccin
inactiv
log
goat
log
goat
vaccin
inactiv
plu
tm
develop
igg
titer
log
goat
second
dose
vaccin
boost
serum
igg
respons
goat
although
goat
vaccin
inactiv
exhibit
averag
igg
titer
log
day
post
immun
higher
goat
goat
vaccin
inactiv
plu
tm
develop
signific
titer
serum
igg
specif
log
approxim
higher
titer
measur
goat
vaccin
inactiv
least
higher
goat
titer
specif
measur
sera
vaccin
goat
second
immun
ie
day
studi
rel
contribut
igg
subclass
observ
igg
respons
goat
vaccin
inactiv
produc
low
titer
subclass
log
log
respect
fig
averag
higher
background
level
goat
log
contrast
goat
vaccin
inactiv
plu
tm
exhibit
titer
serum
log
averag
higher
goat
titer
serum
log
averag
higher
goat
addit
goat
vaccin
plu
tm
titer
serum
significantli
higher
fig
vaccin
goat
level
serum
iga
also
studi
elisa
undetect
time
point
test
data
shown
system
immun
system
may
contribut
local
protect
genit
mucosa
antibodi
transud
serum
vagin
secret
sinc
inactiv
plu
tm
vaccin
induc
high
serum
titer
antigenspecif
igg
high
vn
titer
paramet
measur
vagin
wash
collect
vaccin
goat
administr
first
vaccin
dose
ie
sampl
collect
day
none
goat
vaccin
exhibit
detect
vagin
igg
log
fig
anim
vaccin
inactiv
plu
tm
exhibit
low
titer
vagin
igg
log
averag
higher
goat
log
fig
administr
second
vaccin
dose
ie
sampl
collect
day
result
significantli
elev
titer
vagin
igg
log
goat
vaccin
inactiv
plu
tm
antibodi
titer
averag
higher
goat
fig
day
post
immun
vagin
igg
remain
undetect
goat
vaccin
inactiv
note
level
vagin
igg
three
group
goat
differ
despit
presenc
similar
level
albumin
vagin
sampl
data
shown
suggest
vagin
igg
goat
vaccin
inactiv
plu
tm
reflect
higher
level
serum
igg
group
anim
rather
result
augment
mucos
permeabl
level
vn
activ
vagin
wash
vaccin
goat
undetect
even
second
immun
ie
day
like
due
dilut
vagin
antibodi
collect
sampl
vagin
iga
detect
anim
respons
vaccin
time
data
shown
product
ifngamma
antigenspecif
pbmc
goat
vaccin
inactiv
plu
tm
profil
ifngamma
secret
pbmc
isol
vaccin
goat
follow
second
immun
ie
day
studi
cultur
supernat
stimul
shown
fig
pbmc
isol
goat
vaccin
inactiv
goat
produc
detect
level
ifngamma
upon
antigenstimul
vitro
goat
vaccin
inactiv
plu
tm
exhibit
signific
level
solubl
ifngamma
pgml
respons
vitro
antigen
stimul
level
approxim
higher
either
goat
goat
vaccin
inactiv
pgml
cultur
alway
undetect
respons
stimul
data
shown
mitogenstimul
pbmc
cultur
vaccin
goat
goat
secret
similar
amount
ifngamma
data
shown
indic
abil
produc
ifngamma
intact
compar
goat
frequenc
ifngamma
produc
cell
measur
elispot
fig
pbmc
goat
vaccin
inactiv
plu
tm
develop
significantli
ifngamma
produc
cell
pbmc
rel
either
goat
goat
vaccin
inactiv
ifngamma
pbmc
determin
efficaci
inactiv
plu
tm
vaccin
vaccin
goat
vagin
infect
ml
virul
suspens
tcid
ml
two
week
second
immun
monitor
daili
day
order
record
sever
diseas
vagin
viru
shed
kinet
paramet
determin
area
curv
auc
calcul
goat
statist
comparison
goat
vagin
infect
use
unvaccin
control
figur
show
day
day
post
challeng
goat
immun
inactiv
goat
shed
titer
challeng
viru
measur
standard
cellcultur
method
significantli
differ
particular
day
day
post
challeng
group
goat
show
similar
trend
activ
local
viru
replic
shed
increas
titer
challeng
viru
reach
maxim
level
day
log
day
log
day
goat
log
day
log
day
goat
vaccin
inactiv
group
goat
shed
challeng
viru
start
decreas
day
post
challeng
reach
undetect
level
day
hand
time
point
post
challeng
vagin
shed
detect
standard
cellcultur
test
goat
vaccin
inactiv
plu
tm
fig
shed
challeng
viru
goat
vaccin
inactiv
plu
tm
statist
differ
goat
goat
vaccin
inactiv
parallel
realtim
pcr
assay
perform
dna
extract
vagin
swab
collect
daili
challeng
goat
order
detect
quantit
number
genom
figur
show
day
day
post
challeng
number
genom
detect
vagin
swab
goat
immun
differ
significantli
goat
particular
day
day
post
challeng
goat
vaccin
inactiv
goat
exhibit
trend
activ
local
viru
replic
number
genom
increas
day
day
post
challeng
genom
peak
day
post
challeng
goat
number
genom
peak
day
post
challeng
goat
vaccin
inactiv
group
goat
number
genom
progress
decreas
day
day
post
challeng
reach
level
day
approxim
lower
measur
day
post
challeng
goat
approxim
lower
measur
day
post
challeng
goat
vaccin
inactiv
interest
note
vagin
sampl
obtain
goat
vaccin
inactiv
goat
dna
remain
detect
day
day
post
challeng
fig
titrat
infecti
viru
cellcultur
test
gave
neg
result
major
goat
fig
differ
vagin
genom
profil
observ
goat
vaccin
inactiv
plu
tm
fig
fact
decreas
number
genom
detect
day
day
post
challeng
day
post
challeng
genom
becam
undetect
vagin
swab
group
vaccin
goat
fig
addit
number
vagin
genom
measur
day
day
post
challeng
significantli
differ
goat
well
goat
immun
inactiv
remark
goat
vaccin
inactiv
plu
tm
infecti
challeng
viru
undetect
standard
cellcultur
test
day
day
post
challeng
fig
probabl
due
neutral
viru
whose
genom
detect
antigenspecif
vagin
antibodi
fig
addit
number
genom
detect
day
post
challeng
vagin
swab
goat
vaccin
inactiv
plu
tm
approxim
lower
measur
swab
naiv
goat
approxim
lower
measur
goat
vaccin
inactiv
fig
sinc
anim
experiment
infect
ident
amount
challeng
viru
differ
level
vagin
genom
day
post
challeng
could
due
immun
respons
induc
adjuv
vaccin
could
interfer
viru
replic
clinic
score
also
record
vagin
challeng
monitor
clinic
efficaci
vaccin
formul
fig
goat
vaccin
inactiv
without
adjuv
show
significantli
less
sever
clinic
diseas
character
milder
lesion
faster
heal
compar
anim
show
classic
sign
kinet
herpet
diseas
challeng
virul
produc
overt
diseas
evid
upon
visual
inspect
vagina
goat
vaccin
inactiv
plu
tm
fig
howev
sinc
histolog
analysi
perform
vagin
mucosa
frequenc
ifngamma
produc
cell
goat
vagin
challeng
virul
determin
effect
experiment
infect
ifngamma
product
pbmc
isol
challeng
goat
three
week
postchalleng
frequenc
ifngamma
secret
cell
measur
vitro
stimul
depict
figur
ifngamma
produc
cell
detect
similar
level
goat
vaccin
inactiv
ifngamma
pbmc
goat
ifngamma
pbmc
frequenc
ifngamma
produc
cell
goat
vaccin
inactiv
plu
tm
ifngamma
pbmc
significantli
higher
averag
higher
observ
goat
goat
vaccin
inactiv
addit
frequenc
ifngamma
produc
cell
remain
stabl
vagin
challeng
goat
vaccin
inactiv
plu
tm
fig
fig
determin
whether
inactiv
plu
tm
vaccin
influenc
establish
latenc
sacral
ganglia
isol
challeng
goat
subject
realtim
pcr
assay
detect
quantit
latent
load
report
previous
dna
variabl
detect
five
pair
sacral
ganglia
isol
goat
similar
trend
observ
goat
vaccin
inactiv
fig
therebi
confirm
amount
distribut
latent
sacral
ganglia
appear
relat
sever
clinic
sign
diseas
follow
challeng
goat
latent
genom
abundantli
found
second
third
fourth
pair
sacral
ganglia
approxim
time
time
time
limit
detect
realtim
pcr
assay
second
third
fourth
ganglia
respect
log
first
pair
log
second
pair
log
third
pair
log
fourth
pair
log
fifth
pair
addit
goat
genom
detect
first
sacral
ganglia
averag
number
genom
ganglia
time
limit
detect
realtim
pcr
assay
fifth
sacral
ganglia
averag
number
genom
ganglia
time
limit
detect
realtim
pcr
assay
interest
note
goat
vaccin
inactiv
plu
tm
genom
undetect
sacral
ganglia
examin
particular
undetect
first
sacral
ganglia
number
genom
latent
infect
ganglion
time
limit
detect
realtim
pcr
assay
ii
second
sacral
ganglia
iii
third
sacral
ganglia
iv
fourth
sacral
ganglia
number
genom
latent
infect
ganglion
less
time
limit
detect
realtim
pcr
assay
v
fifth
sacral
ganglia
goat
vaccin
inactiv
plu
tm
number
latent
genom
second
third
fourth
fifth
pair
sacral
ganglia
significantli
differ
goat
inde
four
six
goat
vaccin
plu
tm
genom
undetect
five
pair
sacral
ganglia
remain
two
goat
detect
latent
dna
one
singl
ganglion
one
goat
first
left
ganglion
one
goat
fourth
right
ganglion
challeng
c
data
arithmet
mean
sd
cumul
independ
experi
perform
describ
materi
method
total
goat
group
total
goat
inactiv
vaccin
group
total
goat
inactiv
plu
tm
vaccin
group
b
c
doubl
asterisk
denot
probabl
p
shed
titer
number
genom
b
clinic
score
c
goat
vaccin
inactiv
plu
tm
equival
goat
probabl
p
observ
shed
titer
number
genom
b
clinic
score
c
goat
vaccin
inactiv
plu
tm
compar
goat
vaccin
inactiv
c
singl
asterisk
denot
probabl
p
clinic
score
goat
vaccin
inactiv
equival
goat
data
depict
b
c
use
calcul
auc
order
perform
statist
analys
statist
differ
calcul
oneway
anova
test
follow
tukey
posthoc
test
figur
ifngamma
sfc
pbmc
isol
goat
subcutan
vaccin
inactiv
challeng
vagin
virul
vaccin
given
day
day
goat
challeng
vagin
two
week
follow
second
vaccin
ml
virul
suspens
tcid
ml
describ
materi
method
blood
drawn
three
week
postchalleng
pbmc
isol
stimul
vitro
describ
materi
method
frequenc
ifngamma
spot
form
cell
sfc
measur
elispot
data
arithmet
mean
sd
cumul
independ
experi
perform
describ
materi
method
total
goat
group
total
goat
inactiv
vaccin
group
total
goat
inactiv
plu
tm
vaccin
group
singl
asterisk
denot
probabl
p
ifngamma
sfc
goat
vaccin
inactiv
plu
tm
equival
goat
probabl
p
observ
ifngamma
sfc
goat
vaccin
inactiv
plu
tm
compar
goat
vaccin
inactiv
statist
differ
calcul
oneway
anova
test
follow
tukey
posthoc
test
studi
subcutan
administr
whole
inactiv
vaccin
plu
tm
abl
confer
effect
protect
vagin
challeng
goat
vaccineinduc
immun
respons
protect
reduc
replic
challeng
viru
genit
mucosa
undetect
level
significantli
reduc
establish
latenc
sacral
ganglia
challeng
sinc
latent
viral
load
relev
factor
predict
reactiv
rate
anim
latent
infect
hsv
present
result
suggest
vaccin
inactiv
plu
tm
could
least
influenc
rate
recurr
infect
therebi
reduc
transmiss
infect
anim
flock
knowledg
first
studi
show
similar
level
protect
alphaherpesviru
could
achiev
natur
host
vaccin
tm
detergentstabil
oilinwat
emuls
consist
small
drop
oil
squalen
surround
monolay
nonion
deterg
tm
abl
increas
immunogen
sever
type
antigen
promot
antibodi
cellmedi
immun
respons
excel
safeti
record
inde
licens
human
use
european
union
compon
season
pandem
inject
human
fluvaccin
adjuv
tm
administ
mostli
intramuscular
rout
sever
anim
speci
rodent
nonhuman
primat
though
data
rumin
limit
immunogen
vaccin
efficaci
intramuscular
deliveri
muscl
cell
shown
target
tm
adjuv
activ
could
associ
activ
recruit
antigen
present
cell
inject
site
high
efficaci
tm
observ
present
studi
follow
subcutan
administr
inactiv
could
due
crucial
role
play
epiderm
dermal
dendrit
cell
prime
cell
addit
use
whole
viru
immunogen
rather
singl
glycoprotein
could
contribut
observ
high
efficaci
due
presenc
natur
tlr
ligand
vaccin
regard
human
trial
shown
subunit
vaccin
contain
gb
gd
unabl
confer
full
protect
human
howev
underlin
although
veterinari
field
use
classic
whole
inactiv
viru
immunogen
could
practic
less
expens
use
individu
antigen
studi
mandatori
order
identifi
potenti
protect
antigen
could
test
immunogen
efficaci
vaccin
protocol
present
studi
suggest
igg
produc
follow
parenter
immun
goat
could
transud
serum
vagin
secret
contribut
protect
immun
vagin
infect
presenc
agspecif
igg
preferenti
site
entri
would
provid
first
line
defens
infect
could
implement
physiolog
increas
serum
transud
occur
figur
distribut
quantit
genom
dna
sacral
ganglia
goat
vaccin
inactiv
challeng
virul
vaccin
given
day
day
goat
challeng
vagin
two
week
follow
second
vaccin
ml
virul
suspens
tcid
ml
describ
materi
method
five
pair
sacral
ganglia
excis
one
month
challeng
dna
extract
individu
ganglion
detect
quantit
number
genom
realtim
pcr
data
arithmet
mean
sem
cumul
independ
experi
ie
experi
experi
perform
describ
materi
method
total
goat
group
total
goat
inactiv
vaccin
group
total
goat
inactiv
plu
tm
vaccin
group
white
circl
right
ganglia
black
circl
left
ganglia
singl
asterisk
denot
probabl
p
number
genom
second
fifth
pair
ganglia
goat
vaccin
inactiv
plu
tm
equival
goat
doubl
asterisk
denot
probabl
p
number
genom
third
fourth
pair
ganglia
goat
vaccin
inactiv
plu
tm
equival
goat
statist
differ
calcul
oneway
anova
test
follow
tukey
posthoc
test
vagin
herpet
infect
hand
serum
igg
vn
antibodi
could
contribut
protect
intercept
viru
escap
mucosa
inde
remark
serum
antibodi
specif
hsv
shown
neutral
herpesvirus
axon
terminussynaps
ii
promot
intraaxon
neutral
iii
inhibit
axon
spread
epiderm
cell
consist
find
inactiv
plu
tm
vaccin
abl
interfer
replic
genit
mucosa
significantli
reduc
load
latent
sacral
ganglia
inde
anim
ie
immun
inactiv
plu
tm
vaccin
abl
reduc
establish
latenc
undetect
level
five
pair
sacral
ganglia
sever
studi
immun
vaccin
well
studi
immun
elicit
inactiv
whole
mcmv
vaccin
shown
antigenspecif
antibodi
respons
produc
immun
abl
limit
sever
diseas
caus
herpesvirus
cell
respons
play
major
role
control
primari
infect
reactiv
result
present
studi
seem
extend
observ
also
inde
immun
serum
antibodi
gener
follow
immun
seem
provid
partial
protect
genit
diseas
eg
occur
goat
vaccin
inactiv
appear
leav
unab
acut
viral
replic
genit
mucosa
therebi
allow
establish
latent
infect
sacral
ganglia
data
report
suggest
goat
vaccin
inactiv
plu
tm
vagin
igg
ifngamma
product
associ
protect
immun
vagin
infect
although
rel
contribut
antibodi
mucos
andor
system
ifngamma
product
protect
vagin
challeng
remain
specif
address
futur
studi
adjuv
tm
abl
induc
high
level
antigenspecif
ifngamma
key
solubl
mediat
control
resolut
infect
although
ifngamma
major
cytokin
produc
helper
lymphocyt
induc
ctl
futur
studi
necessari
determin
contribut
pbmc
subset
eg
nk
ifngamma
product
goat
vaccin
inactiv
plu
tm
addit
analysi
expand
cytokin
chemokin
test
whether
solubl
mediat
contribut
protect
observ
goat
vaccin
inactiv
plu
tm
two
caveat
current
studi
challeng
perfom
two
week
follow
second
immun
ii
femal
goat
vaccin
futur
studi
employ
larger
number
anim
sex
longer
time
interv
allow
vaccin
challeng
studi
would
determin
protect
effect
elicit
inactiv
plu
tm
vaccin
persist
longer
period
could
prove
vaccin
also
effect
male
conclus
first
studi
show
tm
goat
provid
effect
adjuv
activ
administ
subcutan
inactiv
vaccin
ii
induc
high
level
ifngamma
vaccinespecif
pbmc
report
human
perspect
due
excel
safeti
efficaci
record
tm
current
studi
could
help
design
new
vaccin
pet
hors
safeti
reactogen
primari
concern
effect
vaccin
infecti
diseas
need
eg
felin
leukemia
viru
felin
canin
coronaviru
canin
equin
herpesviru
